MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED (MVP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MVP

MVP - MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.17
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.74

12 Aug
2025

0.030

OPEN

$0.73

4.23%

HIGH

$0.75

77,363

LOW

$0.69

TARGET
$0.81 9.5% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MVP: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 46.3 - 1.4 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/03 - ex-div 2c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-46.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx33.1 M
Book Value Per Share xxxxxxxxxxxxxxx51.6
Net Operating Cash Flow xxxxxxxxxxxxxxx-10.8 M
Net Profit Margin xxxxxxxxxxxxxxx-123.66 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-64.53 %
Return on Invested Capital xxxxxxxxxxxxxxx-62.50 %
Return on Assets xxxxxxxxxxxxxxx-47.32 %
Return on Equity xxxxxxxxxxxxxxx-64.53 %
Return on Total Capital xxxxxxxxxxxxxxx-25.58 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-11.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx9 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx10 M
Price To Book Value xxxxxxxxxxxxxxx0.76

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx3.2 M
Capex % of Sales xxxxxxxxxxxxxxx9.56 %
Cost of Goods Sold xxxxxxxxxxxxxxx36 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx14 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

01/08/2025

1

Speculative Buy

$0.81

9.46%

The highlight of Medical Developments International's update, Bell Potter notes, was a $10.7m turnaround in operating cash flow, thanks to pricing gains and operational efficiencies.

FY25 unaudited revenue largely met the broker's forecast as better-than-expected Penthrox revenue offset lower Respiratory revenue.

A key catalyst is the decision by Ireland's HPRA on expanding the Penthrox drug's usage to six years of age from adults currently. The broker expects this in August, with other European approvals to follow over the next 12 months.

Speculative Buy. Target rises to 81c from 80c on roll-forward.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.40 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.10 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

MVP STOCK CHART

FNArena News on MVP

1
Weekly Ratings, Targets, Forecast Changes – 02-05-25

May 05 2025 - Weekly Reports
2
Weekly Ratings, Targets, Forecast Changes – 28-03-25

Mar 31 2025 - Weekly Reports
3
FNArena Corporate Results Monitor – 01-09-2023

Sep 01 2023 - Australia
4
Australian Broker Call *Extra* Edition – Mar 08, 2023

Mar 08 2023 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Nov 01, 2022

Nov 01 2022 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
2
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
3
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
4
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
5
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
6
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
7
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
8
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
9
CSL Shares Breaking Free

Jul 23 2024 - Technicals
10
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps